|
1.
|
SS HechtTobacco smoke carcinogens and lung
cancerJ Natl Cancer
Inst9111941210199910.1093/jnci/91.14.119410413421
|
|
2.
|
R RosellA VergnenegreB LiuBiomarkers in
lung oncologyPulm Pharmacol
Ther23508514201010.1016/j.pupt.2010.05.00320471486
|
|
3.
|
JT LouieCiprofloxacin: an oral quinolone
for the treatment of infections with gram-negatine pathogens.
Committee on Antimicrobial Agents. Canadian Infectious Disease
SocietyCMAJ15066967619948313286
|
|
4.
|
N SipsasC KosmasP ZiakasComparison of two
oral regiments for the outpatient treatment of low-risk cancer
patients with chemotherapy-induced neutropenia and fever:
Ciprofloxacin plus cefuroxime axetil versus ciprofloxacin plus
amoxicillin/clavulanateScand J Infect
Dis39786791200710.1080/00365540701367769
|
|
5.
|
S HaraguchiM HiokiK YamashitaCiprofloxacin
penetration into the pulmonary parenchyma in Japanese patientsSurg
Today37282284200710.1007/s00595-006-3393-417387558
|
|
6.
|
A DalhoffImmunomodulatory activities of
fluoroquinolonesInfection33S55S70200510.1007/s15010-005-8209-8
|
|
7.
|
K DrlicaMechanism of fluoroquinolone
actionCurr Opin
Microbiol2504508199910.1016/S1369-5274(99)00008-910508721
|
|
8.
|
T KloskowskiN GurtowskaM NowakR
JoachimiakA BajekJ OlkowskaT DrewaThe influence of ciprofloxacin on
A549, HepG2, A375.S2, B16 and C6 cell lines in vitroActa Pol
Pharm68859865201110.5506/APhysPolB.42.85922125950
|
|
9.
|
T KloskowskiN GurtowskaT DrewaDoes
ciprofloxacin have an obverse and a reverse?Pulm Pharmacol
Ther23373375201010.1016/j.pupt.2010.02.00520211752
|
|
10.
|
N GurtowskaT KloskowskiT
DrewaCiprofloxacin criteria in antimicrobial prophylaxis and
bladder cancer recurrenceMed Sci Monit16218223201020885364
|
|
11.
|
T KloskowskiJ OlkowskaA NazlicaT DrewaThe
influence of ciprofloxacin on hamster ovarian cancer cell line CHO
AA8Acta Pol Pharm67345349201020635529
|
|
12.
|
N KeX WangX XuYA AbassiThe xCELLigence
system for real-time and label-free monitoring of cell
viabilityMethods Mol
Biol7403343201110.1007/978-1-61779-108-6_621468966
|
|
13.
|
RE GonzalezCU LimK ColeCH BianchiniGP
SchoolsBE DavisI WadaIB RoninsonEV BroudeEffects of conditional
depletion of topoisomerase II on cell cycle progression in
mammalian cellsCell
Cycle1035053514201110.4161/cc.10.20.1777822067657
|
|
14.
|
P BenesL KnopfovaF TrckaInhibition of
topoisomerase IIα: Novel function of wedelolactoneCancer
Lett30329382011
|
|
15.
|
R SrivastavaApoptosis, Cell Signaling, and
Human DiseasesHumana PressTotowa, NJ2007
|
|
16.
|
EJ CalabreseLA BaldwinHormesis: U-shaped
dose responses and their centrality in toxicologyTrends in
Pharmacol Sci22285291200110.1016/S0165-6147(00)01719-311395156
|
|
17.
|
A GürbayF HincaA FavierCytotoxic effect of
ciprofloxacin in primary culture of rat astrocytes and protection
by vitamin EToxicology2295461200717098346
|
|
18.
|
O AranhaDP WoodFU SarkarCiprofloxacin
mediated cell growth inhibition, S/G2-M cell cycle arrest, and
apoptosis in human transitional cell carcinoma of the bladder cell
lineClin Cancer Res6891900200010741713
|
|
19.
|
ER MondalSK DasP MukherjeeComparative
evaluation of antiproliferative activity and induction of apoptosis
by some fluoroquinolones with a human non-small cell lung cancer
cell line in cultureAsian Pac J Cancer Prev5196204200415244525
|
|
20.
|
R RohwedderT BerganE CarusoSB
ThorsteinssonH Della TorreH SchollPenetration of ciprofloxacin and
metabolites into human lung, bronchial and pleural tissue after 250
and 500 mg oral
ciprofloxacinChemotherapy37229238199110.1159/0002388601790720
|
|
21.
|
IS KourbetiDE AlegakisS MarakiG
SamonisImpact of prolonged treatment with high-dose ciprofloxacin
on human gut flora: a case reportJ Med Case
Rep4111201010.1186/1752-1947-4-11120409330
|
|
22.
|
TR UtrupEW MuellerDP HealyRA CallcutJD
PetersonWE HurfordHigh-dose ciprofloxacin for serious gram-negative
infection in an obese, critically III patient receiving continuous
venovenous hemodiafiltrationAnn
Pharmacother4416601664201010.1345/aph.1P234
|
|
23.
|
S ChonoT TaninoT SekiK
MorimotoPharmacokinetic and pharmacodynamic efficacy of
intrapulmonary administration of ciprofloxacin for the treatment of
respiratory infectionsDrug Metab
Pharmacokinet228895200710.2133/dmpk.22.8817495415
|
